UiPath hits an inflection point with stabilizing SaaS, AI roadmap, Maestro platform upsells, top partnerships, and clean ...

Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.

Small- and mid-cap AI plays - PATH, FIVN, QLYS, TDC and BB lagged last year but could become game changers in 2026 as AI infrastructure demand stays bullish.

Testing an AI agent for donor tissue screening at Evergen surfaces more than technical performance questions. The project ...